Details for New Drug Application (NDA): 212878
✉ Email this page to a colleague
NDA 212878 describes CHLORTHALIDONE, which is a drug marketed by Abbott, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Ani Pharms, Appco, Ascot, Barr Labs Inc, Chartwell Rx, Cosette, Dava Pharms Inc, Inventia, Ivax Pharms, Kv Pharm, Mankind Pharma, Mutual Pharm, Mylan, Novast Labs, Pharmobedient, Pioneer Pharms, Purepac Pharm, Sandoz, Sun Pharm Industries, Sunny, Superpharm, Umedica, Unichem, Usl Pharma, Vangard, Warner Chilcott, Watson Labs, and Zydus Pharms, and is included in fifty-eight NDAs. It is available from thirty-five suppliers. Additional details are available on the CHLORTHALIDONE profile page.
The generic ingredient in CHLORTHALIDONE is chlorthalidone. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the chlorthalidone profile page.
The generic ingredient in CHLORTHALIDONE is chlorthalidone. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the chlorthalidone profile page.
Summary for 212878
| Tradename: | CHLORTHALIDONE |
| Applicant: | Pharmobedient |
| Ingredient: | chlorthalidone |
| Patents: | 0 |
Pharmacology for NDA: 212878
| Physiological Effect | Increased Diuresis |
Medical Subject Heading (MeSH) Categories for 212878
Suppliers and Packaging for NDA: 212878
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CHLORTHALIDONE | chlorthalidone | TABLET;ORAL | 212878 | ANDA | TAGI Pharma, Inc. | 51224-018 | 51224-018-50 | 100 TABLET in 1 BOTTLE (51224-018-50) |
| CHLORTHALIDONE | chlorthalidone | TABLET;ORAL | 212878 | ANDA | TAGI Pharma, Inc. | 51224-018 | 51224-018-70 | 1000 TABLET in 1 BOTTLE (51224-018-70) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Feb 24, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
